Table 2.
Cost-effectiveness and Fixed Budget Analysis of Treating Noncirrhotic, Treatment-Naïve, Genotype 1 HCV-Infected Individuals
| Cost, $ | Incr. Cost, $ | QALY | Incr. QALY | ICER, $ | % SVR | No. Treated w/$10 000 000 | |
|---|---|---|---|---|---|---|---|
| Black patients | |||||||
| Not treated | 182 000 | - | 10.98 | - | - | 0 | 0 |
| 8-wk | 225 000 | 43 700 | 15.16 | 4.18 | 10 400 | 97.2 | 261 |
| 12-wk | 244 000 | 18 700 | 15.24 | 0.09 | 218 000 | 99.2 | 175 |
| Nonblack patients | |||||||
| Not treated | 182 000 | - | 10.98 | - | - | 0 | 0 |
| 8-wk | 225 000 | 43 600 | 15.18 | 4.20 | 10 400 | 97.6 | 261 |
| 12-wk | 244 000 | 18 900 | 15.19 | 0.01 | 2 860 000 | 97.8 | 175 |